RxDoctor Payments Data

Thomas Cole, MD

Family Medicine · Huntsville, TXNPI 1265525851

Payments from drug & device makers

$1,772in general payments, 2019–2025

Across 47 payments — averaging $37.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$967
  • Pfizer$279
  • Amgen$134
  • Boehringer Ingelheim$120
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$80
  • AbbVie$62
  • plus $131 from 5 others

What the payments were for

  • Food & beverage$1,73198%
  • Education$412%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,772 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$8,513
Medicare patients
49
Services billed
205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide154$183,346
MounjaroTirzepatide84$88,081
FarxigaDapagliflozin Propanediol120$80,482
JardianceEmpagliflozin61$56,694
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$43,703
Budesonide ErBudesonide17$39,142
Breztri AerosphereBudesonide/Glycopyr/Formoterol56$34,632
TrulicityDulaglutide28$30,630
EliquisApixaban28$29,266
LinzessLinaclotide42$28,044
XareltoRivaroxaban19$23,039
JanuviaSitagliptin Phosphate35$22,365
GlyxambiEmpagliflozin/Linagliptin29$17,086
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen368$16,657
TradjentaLinagliptin28$15,354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$967$125,818221 claims
Lilly USA, LLCMounjaro, Trulicity$51$118,712112 claims
Boehringer IngelheimJardiance, Glyxambi, Tradjenta, Combivent Respimat$120$101,647138 claims
GSKTrelegy Ellipta$12$43,70355 claims
PfizerEliquis$279$29,26628 claims
AbbVieLinzess$62$28,04442 claims
MerckJanuvia$12$22,36535 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Huntsville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →